EP1315805A2 - Verfahren zur herstellung von menschlichen thrombopoietin-polypeptiden durch säugetierzellkulturen - Google Patents

Verfahren zur herstellung von menschlichen thrombopoietin-polypeptiden durch säugetierzellkulturen

Info

Publication number
EP1315805A2
EP1315805A2 EP01960992A EP01960992A EP1315805A2 EP 1315805 A2 EP1315805 A2 EP 1315805A2 EP 01960992 A EP01960992 A EP 01960992A EP 01960992 A EP01960992 A EP 01960992A EP 1315805 A2 EP1315805 A2 EP 1315805A2
Authority
EP
European Patent Office
Prior art keywords
cells
htpo
dna
etpo
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01960992A
Other languages
English (en)
French (fr)
Other versions
EP1315805B1 (de
Inventor
Alfonso Cayota Guzicovsky
Carlos Alberto Robello Porto
Otto Franz Pritsch Albisu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1315805A2 publication Critical patent/EP1315805A2/de
Application granted granted Critical
Publication of EP1315805B1 publication Critical patent/EP1315805B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand

Definitions

  • progenitor pluripotent cells are capable of autoduplicating without differentiating themselves (endoduplication/autoreplication) or capable of generating a series of progenitor cells grouped in 4 principal ways of differentiation: a) erythroid (red blood cells or erythrocytes); b) myeloid (polimorphonuclear leucocytes and monocytes); c) lymphoid (lymphocytes) and d) megakaryiotic (generator of megakaryocytes/platelets).
  • the quantity and cellular type produced by the bone marrow is a process finely regulated by a complex network of cytokines or growth factors that act via membrane-bound receptors on the target cells.
  • cytokines include a heterogeneous group of growth factors including interleukins (among others TNF- ⁇ ,D IL-3, IL-6, IL-8 e IL-11) and glycoproteic hormones called "Colony Stimulating Factors" (Granulocyte Colony stimulating factors and Granulocyte/ acrophage Colony stimulating factors [G-CSF y GM- CSF respectively]); Erythropoietin as stimulation factor of erythrocyte progenitors and Thrombopoietin as stimulator of platelet progenitors.
  • EPO Erythropoietin
  • G-CSF y GM-CSF Colony stimulating factors
  • Interferon- ⁇ Both have been widely used in conjunction with chemotherapeutic agents. Interferons are being used, with certain success, in the treatment of chronic hepatitis, as well as IL-2 in AIDS associated to antiretroviral agents.
  • the circulating blood platelets are produced in the bone marrow and play a crucial role in blood coagulation. Platelets adhere to sites of tissue damage and recruit others to aggregate with it to form the "primary hemostatic plug". In addition, it serves as the surface upon which the coagulation factors are activated to produce a fibrin clot. In the absence of platelets, both of these functions are deficient and bleeding ensues( 1).
  • the generation of platelets implies proliferation and differentiation of bone marrow stem cells, into megakaryocytic cells which will generate the mature platelets (thrombocytes) that normally circulate in peripheral blood.
  • thrombocytopoietic The physiological process by which platelets are generated requires the presence of factors called "Thrombocytopoietic" as growth and development factors from the megakaryocytic-lineage.
  • thrombocytopenia the decrease of the number of platelets (thrombocytopenia) is a great complication related to two relevant situations: a) diseases that affect the normal generation of platelets (primary thrombocytopenia) and B) as a result of complications derived form therapeutic treatment in cancer patients or patients that have received a bone marrow transplant (secondary thrombocytopenia).
  • primary thrombocytopenia diseases that affect the normal generation of platelets
  • secondary thrombocytopenia the production of platelet concentrates from normal donors with the associated biological risk (allergies, infections, immune hypersensitivity).
  • thrombocytopoietic activity has been described (9), including IL-6 and IL-1 1 although they are not specific and have pleiothropic actions.
  • the gene of Human Thrombopoietin (hTPO) has been localized as a single copy, to chromosome 3 (3q26-27). It codifies for a protein of 353 aminoacids (open reading frame of 10590 base pairs), including a signal peptide of 21 amino acids (aa) (63 base pairs).
  • the mature protein has 332 aa (996 bp) and an estimated molecular weight of 38kDa (not glycosilated). It has 6 N-glycosilation sites in order to generate a complete glycosilated protein of 70-80 kDa and a cleavage site, between arginines 153 and 154, where the protein is divided into two domains: a) a highly glycosilated c-terminal domain without homology with known proteins, and b) an EPO-like or N-terminal domain of 153 aa with 23% of identity with EPO. Allowing for conservative aa substitutions, sequence conservation approaches 50%.
  • non-glycosilated form has complete activity in vitro but not in vivo due to a decreased stability and a quick depuration in the circulation.
  • native molecule 70-80 kDa
  • forms of circulating TPO have been described, as a result of its partial proteolysis consisting of forms of 30,25 and 18 kDa, all truncated at the C-terminal domain (9, 11 and 12).
  • the only factor with thrombocytopoietic activity available and approved by the FDA Food and Drug Administration is the human recombinant IL-11.
  • the present invention provides an expression vector replicable in mammalian host cells.
  • the vectors comprise the following operably linked elements: 1) a transcription promoter; 2) the first DNA segment encoding a secretory leader or signal peptide of native hTPO; 3) a second DNA segment encoding the complete hTPO polypeptide; 4) a transcriptional enhancer; 5) polyadenylation signal and 6) a transcription terminator.
  • a cultured eukaryotic cell line containing the DNA construct as disclosed above.
  • the prefered cell line is a mammalian cell.
  • hTPO production procedure that has a murine cell line of plasmocytic origin, transfected with the espression vector previously described.
  • this cell line acquires the capacity to synthesize and secrete a biologically active human recombinant hTPO (rhTPO), identical to its natural counterpart.
  • TPO Thrombopoietin
  • Mpl receptor is mainly present on pluripotent stem cells, megakaryocytes and platelets.
  • hTPO human TPO
  • hTPO encompasses full-length thrombopoietin molecules that exhibit the qualitative biological activities of the intact molecule (receptor binding and in vivo stimulation of platelet production).
  • RNA Ribonucleic Acid
  • reverse transcriptase RNA reverse transcriptase
  • Expression Vector Is a DNA molecule, linear or circular, that comprises a segment encoding a polypepetide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and temrinator sequences.
  • An expression vector may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.
  • Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
  • the term "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator. Replication of expression vectors in a host organism can be autonomous or through integration into the host genome.
  • a secretory peptide is an amino acid sequence that acts to direct the secretion of a mature polypeptide or protein from a cell. Secretory peptides are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. Very often the secretory peptide is cleaved from the mature protein during secretion in one or more cleavage events. Such secretory peptides contain processing sites that allow cleavage of the secretory peptides from the mature proteins as they pass through the secretory pathway.
  • RNA polimerase recognized by RNA polimerase in order to initiate the gene transcription and generate the corresponding messenger RNA.
  • Transfection It is the process by which an eukaryotic cell is genetically modified through the introduction of DNA constructions that are capable of producing a protein that is not normally produced by that cell. They are described as "transfected cells”.
  • the present invention provides the material and methods used in order to obtain a human recombinant TPO with proved biological activity and whose general experimental design had the following steps:
  • Total cDNA was obtained from RNA by a process of reverse transcription and the complete sequence of hTPO was amplified from cDNA by using specific primers (Table II).
  • That vector is introduced, by conventional electroporation techniques, in a mammalian cell line that can be cultivated in vitro.
  • Neomycin antibiotic is added to the artificial medium in which cells are grown.
  • the cells that have successfully incorporated the expression vector are selected because they bear the gene enconding resistance to the antibiotic neomycin.
  • the nucleotide sequence identified as NM000460 and the aminoacidic sequence identified as SEQ N°1 that corresponds to the mature hTPO is represented in Table I (5).
  • the sequences NM 000460 and SEQ N°1 represent a single allele of hTPO from which different allele variants may exist. Those variants can be obtained from cloned cells, human tissues or DNA preparations. That sequence was used to obtain primers necessary to amplify the specific TPO material and its posterior cloning and purification. In the present invention we proceed to clone and obtain the cDNA that corresponds to the complete hTPO including its signal peptide from normal hepatic tissue. No partial or modified fragments of the same sequence were used in the present invention.
  • the expression vector constructed in this invention sequentially contains: a) a transcription promoter, derived from a variable gene from a kappa chain of human immunoglobulins obtained from a genomic library of human B lymphocytes ; b) a first segment of DNA encoding the specific signal peptide of hTPO; c) a second segment of DNA encoding the full-length mature hTPO polypeptide; d) a transcriptional enhancer, derived from an intronic region from a human kappa gene (obtained from a genomic library of human B lymphocytes); e) a polyadenylation signal; f) a transcription terminator; g) the complete sequence of the resistance gene to ampicillin, as a selection marker in bacterial systems; h) the complete sequence of the resistance gene to neomycin, as a selection marker in eukaryotic cell systems; I) a bacterial replication origin that allows its expansion in bacteria.
  • the direct product of transcription and transduction of the DNA segment that codes the mature hTPO polypeptide may depend on a post-transductional processing adding different chemical groups that include, among others, the union of carbohydrates through chemical bonds called "N-linked glycosilation or O-linked glycosilation".
  • N-linked glycosilation or O-linked glycosilation The exact nature of this post- transductional modifications will be determined mostly but not exclusively, by the type of host cell used to produce recombinant hTPO.
  • Suitable host cells for use within the present invention include any type of eukaryotic cell that can be engineered to express heterologous DNA, can be grown in culture, and has an efficient secretory pathway.
  • the preferred cells that follow these requirements are those derived from murine myeloma which are kown in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland (ATCC).
  • ATCC American Type Culture Collection
  • the line X-63 P63X63Ag.563 (ATCC N° CRL-1580) and SP2 (ATCC N° CRL-1581 and CRL-8287).
  • a DNA sequence encoding a secretory leader is used in combination with a DNA sequence encoding a hTPO polypeptide.
  • the signal peptide used was the corresponding to native hTPO (aminoacidic sequence appears in bolded font over SEQ 1 in Table I).
  • strong promoters of transcription are required, such as immunglobulins, viral promoters derived from SV40, adenovirus or citomegalovirus that are included here in order to have a reference.
  • Drug selection is a widely used method that allows selecting those mammalian culture cells that have successfully incorporated the expression vector.
  • transfectants Such cells are commonly referred to as "transfectants".
  • Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable transfectants".
  • a preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification”. Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes.
  • Other drug resistance genes that can be used may be the hygromycine, multi-drug resistance gene, dihydrofolate reductase and puromycin acetlyltransferase.
  • exogenous DNA there are many methods to incorporate exogenous DNA into mammalian cells, among which we highlight: a) calcium phosphate-mediated transfection; b)electroporation (14); c) DEAE-dextrane mediated transfection (Ausubel et al., eds. Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987) and d) cationic lipid-mediated transfection.
  • the preferred method used in the present invention is electroporation.
  • the transfected cells are cultured in conventional media, which contain essential nutrients for cellular growth, as well as the necessary antibiotics in order to select the cells that have incorporated exogenous DNA.
  • the hTPO polypeptide prepared according to the present invention can be used therapeutically wherever it is desirable to increase platelet production, such as in the treatment of thrombocytopenia induced by different diseases including aplastic anemia, myelodisplastic syndromes, chemotherapy or congenital thrombocytopenias.
  • the thrombocytopenia is characterized by a decrease in the number of circulating blood platelets and is manifested as increased skin and mucosal bleedings.
  • Lowered platelet counts can result from, for example, defects in platelet production, abnormal platelet distribution, dilutional losses due to massive transfusions, or abnormal destruction of platelets.
  • certain malignancies can impair platelet production and platelet distribution.
  • Thrombocytopenia may also arise from various platelet autoimmune disorders induced by drugs, neonatal alloimmunity or platelet transfusion alloimmunity.
  • hTPO polypeptides can reduce or eliminate the need for transfusion, thereby reducing the incidence of platelet alloimmunity.
  • Abnormal destruction of platelets can result from: 1) increased platelet consumption in vascular grafts or traumatized tissue; or 2) immune mechanisms associated with, for example, drug-induced thromocytopenia, idiopathic thrombocytopenic purpura (ITP), autoimmune diseases, hematologic disorders such as leukemia and lymphoma, or metastatic cancers involving bone marrow.
  • ITP idiopathic thrombocytopenic purpura
  • Other indications for hTPO include aplastic anemia and rug-induced marrow suppression resulting from, for example, chemotherapy or treatment of HIV infection with AZT.
  • rhTPO can be also associated with other cytokines such as SCF, IL-3, IL-6, IL-11 or GM-CSF.
  • the therapeutic doses of rhTPO are in the range of 0,1 a 100 ⁇ g/kg per day (preferably 0,5 - 50 ⁇ g/kg a day). The exact doses must be determined by clinical evaluation in each particular case.
  • the rhTPO is administered for a 28-day period following chemotherapy or bone marrow transplant, or until the number of platelets is more than 20.000/ ⁇ l, preferably 50.000 / ⁇ l.
  • rhTPO polypeptides are also valuable tools for the in vitro study of the differentiation and development of hematopoietic cells, such as for elucidating the mechanisms of cell differentiation and for determining the lineages of mature cells, and may also find utility as a proliferative agent in cell culture.
  • rhTPO polypeptides can also be used ex vivo, such as in autologous marrow culture. Briefly, bone marrow is removed from a patient prior to chemotherapy and treated with rhTPO polypeptides, optionally in combination with one or more other cytokines. The treated marrow is then returned to the patient after chemotherapy to speed the recovery fo the marrow.
  • rhTPO polypeptides can also be used for the ex vivo expansion of marrow or peripheral blood progenitor (PBPC) cells. Prior to chemotherapy treatment, marrow can be stimulated with stem cell factor (SCF) or G-CSF to release early progenitor cells into peripheral circulation.
  • SCF stem cell factor
  • G-CSF G-CSF
  • progenitors can be collected and concentrated from peripheral blood and then treated in culture with one or more rhTPO polypeptides, optionally in combination with one or more other cytokines, cinluding but not limited to SCF, G-CSF, IL-3, GM-CSF, IL-6 or IL-11 , to differentiate and proliferate into high-density megakaryocyte cultures, which can then be retured to the patient following high-dose chemotherapy.
  • cytokines cinluding but not limited to SCF, G-CSF, IL-3, GM-CSF, IL-6 or IL-11 .
  • rhTPO Another potential use of rhTPO, is its use in several diagnostics that are performed in order to determine the presence of anti-TPO antibodies, which have been demonstrated in autoimmune thrombocytopenias.
  • the present invention is futher illustrated by the following non-limiting examples.
  • RNA obtained from hepatic tissue of a normal adult in order to obtain specific cDNA of hTPO.
  • a fragment of hepatic tissue from a normal adult (50mgrs) was processed in order to isolate total RNA. This process was performed applying classical methods of extraction with guanidine thiocyanate phenol-chloroform. The purity and concentration of total RNA was determined by 260/280 absorbance ratio.
  • cDNA synthesis (reverse transcription) of hTPO specific mRNA. Synthesis of the first stand of cDNA by reverse transcription, was performed from 5ug of total RNA, using synthetic Oligo(dT) ⁇ 2 . 18 and Reverse Transcriptase (Superscript TM II, Gibco-BRL-Life Technologies).
  • the assay was performed in a total volume of 20 ⁇ l containing: 4 ⁇ l buffer 5x (250 mM Tris-HCI pH 8.3; 350 mM KCI; 15 mM MgCI 2 ; 0.1 M DTT); 1 ⁇ l of Oligo (dT) 500 ⁇ g/ml; 2 ⁇ l DTT 0.1 M.; 1 ⁇ l 10 mM dNTPs; 5 ⁇ g total ARN and completing with 20 ⁇ l H 2 O.
  • 4 ⁇ l buffer 5x 250 mM Tris-HCI pH 8.3; 350 mM KCI; 15 mM MgCI 2 ; 0.1 M DTT
  • Oligo (dT) 500 ⁇ g/ml
  • 1 ⁇ l 10 mM dNTPs 5 ⁇ g total ARN and completing with 20 ⁇ l H 2 O.
  • Amplification of the specific cDNA encoding the complete hTPO Amplification of the sequence of interest by "nested PCR” techniques (Polymerase chain reaction). This is done by designing a double pair of primers and a combination of thermostable DNA polymerases in order to amplify the sequence encoding the mature protein that has high specificity and fidelity. In that sense, a high fidelity amplification system was used. This system was composed by the adequate mixture of Taq polymerase and Pow DNA polymerase (EHF; ExpandTM High Fidelity PCR System, Boehringer Mannheim). The sequence of primers used in the two amplification rounds are described in Table II. The amplification reactions were performed in a total volume of 100 ⁇ l by adding:
  • the first round of amplification was performed with the external primers TPO E ⁇ - FOW y TPOEXT-REV (see Table II A) and the reaction was then incubated for 30- amplification cycle (previously incubated for 2 minutes at 95 °C).
  • the second round of amplification was performed with the internal primers TPO F ow y TPOREV (see Table II B) under the same conditions, but substituting 5 ⁇ l of cDNA of the first round for 2 ⁇ l of the first amplification reaction.
  • the reaction conditions were 20 cycle of amplification with previous incubation for 2 minutes at 95°C, described as follows:
  • the purified fragment is incubated for 10 minutes at 72°C with: Taq DNA polymerase, buffer and dATP.
  • the fragment is again extracted and purified using phenol/chroloform extraction, precipitated in ethanol and then resuspended in 20 ⁇ l of H 2 O.
  • the cDNA fragment is ready to be ligated and cloned into an A-T cloning vector system.
  • the enzymatic ligation was incubated for 16 hours at 14°C.
  • Competent E. Co/ strains (One ShotTM TOP10F'; Invitrogen) were transformed with the ligated plasmid.
  • This vectors allowed: a) obtaining bacterial colonies that included the plasmid, due to the presence of the resistance gene to ampicillin; b) identifying bacterial colonies with plasmids containing cDNA inserts encoding hTPO.
  • the inserts were sequenced, in order to be correctly identified, according to the method described by Sanger and cols. (18) The sequenciation was performed completely over both DNA strands.
  • the plasmid preparation corresponding to clone pCR2 TPO-5 was selected to continue the following experimental steps.
  • Neomycin-resistance gene (Neo r ) to positively select the transfected cells in a medium that contains neomycin (G-418)
  • Ampicillin-resistance gene (Amp r )
  • the amplification reaction was performed in a total volume of 50 ⁇ l (Taq DNA polymerase kit; Gibco BRL-Life Technologies):
  • the amplified product is separated and identified using electrophoresis techniques in an agarose gel low fusion (1%).
  • the part of the gel containing the band of 1090 bp was cut and the DNA was isolated and purified (Nucleiclean, Sigma). This was carried out by performing techniques that use the capacity of fiber-glass microspheres in order to strongly bind the DNA in a saturated sodium iodide media which at the same time is capable of dissolving the agarose (16).
  • the DNA is extracted with phenol/chloroform and washed, precipitated with ethanol, being finally resuspended in 15 ⁇ l of H 2 O.
  • the purified eTPO fragment is ligated into the pCR2-1 vector in order to perform enzymatic restriction analysis and nucleotide sequenciation to verify the complete identity of the fragment with the native hTPO according to the following reaction scheme:
  • the reaction is incubated for 16 hours at 4°C.
  • the ligation product is used to transform competent E. Co// strains (One ShotTM TOP10F'; Invitrogen) to allow their expansion according to the vendor's technical specifications.
  • Six bacterial colonies containing the correct plasmid bearing eTPO inserts were identified and isolated. They were called pCR2-eTPO 1 to 6.
  • Minicultures in LB medium with ampicillin were performed in each of them, in order to isolate the plasmidic material (minipreps).
  • Inserts eTPO-1 to 6 were identified and sequenced. This was done using the Bam I restriction profile and then sequenced to verify the complete nucleotide sequence in both DNA strands using the method described by Sanger and cols. (18) in an automated sequenciator (ALF-EXPRESS; Pharmacia). Table I shows the nucleotide sequence identified as "ETPO", that corresponds to pCR2-eTPO2 plasmid, compared to sequence NM000460 (Sauvage et al., 1994). As depicted, the obtained sequence is identical to the one used as reference. The pCR2- eTPO2 plasmid was selected to carry out the subsequent stages. Stage 5
  • the eukaryotic pK expression vector was enzymatically digested using Cla I and Not I before it was ligated to the eTPO fragment. To perform the digestion, the enzymatic reaction was incubated for 4 hours at 37°C as follows:
  • the linearized vector after enzymatic digestion, is separated and identified using electrophoresis techniques with low fusion agarose gel (1 %).
  • the DNA is extracted with phenol/chloroform, washed, and ethanol precipitated, being finally resuspended in 15 ⁇ l H 2 O.
  • the pCR2-eTPO2 was enzymatically digested using Cla I and Not I in order to obtain the eTPO-2 fragment.
  • Cla I and Not I for the digestion the following enzymatic reaction was used which was incubated for 4 hours at 37°C:
  • the linearized vector after enzymatic digestion, is separated from the eTPO 2 fragment using electrophoresis techniques with low fusion agarose gel (1 %).
  • the gel region in which the fragment eTPO 2 is contained was cut and DNA was isolated and purified by techniques that use the capacity of fiber-glass microspheres in order to strongly bind the DNA in a saturated sodium iodide media which at the same time is capable of dissolving the agarose (16).
  • the DNA is extracted with phenol/chloroform, washed, precipitated with ethanol, being finally resuspended in 15 ⁇ l of H 2 O.
  • DNA ligase (Pharmacia) following the supplier's technical specifications.
  • the product of this ligation called pK-eTPO, is purified using phenol/chloroform extraction methods, precipitated with ethanol, being finally resuspended in 15 ⁇ l
  • Transfection of E. Coli (strain XL1), with the constructed pK-eTPO is performed by electroporation.
  • 40 ul of electro-competents XL-1 strain are placed together with 2 ⁇ l of the purified ligation obtained in stage 7.
  • 800 ⁇ l of LB medium are added.
  • an incubation period of 45 min. at 37°C in an orbital incubator at 200 rpm, LB-agar-ampicillin dishes are seeded.
  • Plasmids were extracted using conventional methods ("minipreps") in order to verify the inserts, by amplification and restriction enzyme analysis. In this way a purified plasmid fraction of pK-eTPO was obtained.
  • pKeTPO vector linearization with Puv I selection of the mammalian cell line to be transfected.
  • pK-eTPO the mammalian cell line derived from murine myeloma known as X-63 (P3X63Ag8.653, ATCC N° CRL 1580), was selected, although any cell that is derived from a mammal can be eventually used with this expression plasmid.
  • this one was selected as it has the following advantages: a) it has a high-efficacy synthesis and secretory system of proteins (immunoglobulins) that perfectly adapt to the designed expression vector, in the present invention, as it includes a promoter of immunoglobulins genes associated to an immunoglobulin transcription enhancer. Additionally is capable of undefinitively grow in in vitro culture media such as RPMI-1640 supplemented with fetal bovine serum (FBS) 10%.
  • FBS fetal bovine serum
  • pKeTPO vector was linearized with Pvu I (Boehringer Mannheim), according to the following reaction:
  • reaction was incubated at 37°C during 4 hours and the material was purified using phenol/chloroform extraction, precipitated with ethanol and finally recovered in 10 ⁇ l of H 2 0.
  • the electroporated cells were cultured for 24 hours in RPMI 1640 with 20% FBS at 37°C and 5% CO 2 .
  • Supernatants from culture II resulted weakly positive for rhTPO, and cloning was performed by limit dilution (cell dilution: 0.3 cells/well placed in a 96-well plates in RPM11640 with 20% of FBS and 1 mg/ml neomycin). After 15 days the 58 neomycin-resistant clones were isolated. Supernatants were processed to evaluate rhTPO presence by western blot. The analysis revealed the presence of 16 clones that produced and secret rhTPO. The clone called 2A4 was isolated, as significant quantities of rhTPO were detected in culture supernatants and was again cloned, by limit dilution, in order to assure its clonaility.
  • subclone 16 from 2A4 was selected, being called subclone 24A-16.
  • the production stability of rhTPO using sub clone 24A-16 was tested after 8 weeks of uninterrupted culture (see figure 2).
  • the clone from X-63 cell called 24A-16 and producer of soluble rhTPO in a stable way, will be called Clone X-63 eTPO.
  • TPO concentration by ELISA a kit for human TPO (Quantikine, R&D Systems). It was confirmed that approximate concentration, under standard culture conditions, was 0.5 mcg/ml.
  • the Baf-mpl cell line (deposited September 28, 1994 under the Budapest treaty terms in ATCC N° CRL-11723) corresponds to the murine line Baf-BO3 transfected with the Mpl receptor (TPO receptor).
  • the parental line Baf- BO3 depends on IL-3 and transfected line Baf-mpl depends on IL-3 or TPO.
  • the assay is based on incubating the cells in the presence of different concentrations of cytokines or the supernatant that is being tested during 48 hours.
  • These cells are cultured in liquid medium under conditions that allow differentiation towards the megakaryocytic lineage. These conditions are: FBS-free Iscove culture media supplemented with transferrine, insulin, bovine seroalbumin, liposomes and in the presence of TPO.
  • CD34+ bone marrow cells were cultured in 24-well plates (100.000 cells/well) with different dilutions of standard rhTPO or supernatant of X-63eTPO clone. After 10 days cell proliferation is tested (number of cells) and percentage of megakaryocytic produced by marking them with FITC-conjugated anti-CD41 monoclonal antibodies and analyzed by flow citometry.
  • ETPO represent de sequence of hTPO obtained in the present invention
  • TPOEXT-FOW- Extra forward primer
  • Not-eTPO REV Not-eTPO REV .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP01960992A 2000-08-30 2001-08-23 Verfahren zur herstellung von menschlichen thrombopoietin-polypeptiden durch säugetierzellkulturen Expired - Lifetime EP1315805B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
UY2631700 2000-08-30
UY26317A UY26317A1 (es) 2000-08-30 2000-08-30 Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
PCT/IB2001/001518 WO2002018569A2 (en) 2000-08-30 2001-08-23 Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures

Publications (2)

Publication Number Publication Date
EP1315805A2 true EP1315805A2 (de) 2003-06-04
EP1315805B1 EP1315805B1 (de) 2005-11-16

Family

ID=25546891

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01960992A Expired - Lifetime EP1315805B1 (de) 2000-08-30 2001-08-23 Verfahren zur herstellung von menschlichen thrombopoietin-polypeptiden durch säugetierzellkulturen

Country Status (19)

Country Link
US (1) US7371569B2 (de)
EP (1) EP1315805B1 (de)
JP (1) JP2004507269A (de)
KR (1) KR20030029894A (de)
CN (1) CN1451040A (de)
AR (1) AR035341A1 (de)
AT (1) ATE310081T1 (de)
AU (2) AU2001282376B9 (de)
BR (1) BR0113789A (de)
CA (1) CA2457165A1 (de)
DE (1) DE60115063T2 (de)
DK (1) DK1315805T3 (de)
ES (1) ES2253411T3 (de)
IL (1) IL154690A0 (de)
MX (1) MXPA03002762A (de)
NZ (1) NZ524924A (de)
UY (1) UY26317A1 (de)
WO (1) WO2002018569A2 (de)
ZA (1) ZA200302414B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724908C (en) * 2008-07-23 2017-03-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hgh polyadenylation signal
AU2019240068B2 (en) * 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2021083366A1 (en) * 2019-11-01 2021-05-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1297434C (en) * 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
DE69503849T2 (de) * 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
DE19541450C2 (de) * 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Genkonstrukt und dessen Verwendung
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0218569A2 *

Also Published As

Publication number Publication date
KR20030029894A (ko) 2003-04-16
DE60115063T2 (de) 2006-08-03
JP2004507269A (ja) 2004-03-11
AU2001282376B9 (en) 2006-12-07
CN1451040A (zh) 2003-10-22
ZA200302414B (en) 2004-07-05
AU2001282376B2 (en) 2006-11-09
ES2253411T3 (es) 2006-06-01
US20040072326A1 (en) 2004-04-15
AR035341A1 (es) 2004-05-12
WO2002018569A2 (en) 2002-03-07
DE60115063D1 (de) 2005-12-22
US7371569B2 (en) 2008-05-13
DK1315805T3 (da) 2006-03-27
AU8237601A (en) 2002-03-13
MXPA03002762A (es) 2005-06-30
IL154690A0 (en) 2003-09-17
EP1315805B1 (de) 2005-11-16
NZ524924A (en) 2005-09-30
BR0113789A (pt) 2004-08-17
UY26317A1 (es) 2000-10-31
ATE310081T1 (de) 2005-12-15
CA2457165A1 (en) 2002-03-07
WO2002018569A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
AU704266B2 (en) Thrombopoietin
Kaushansky Thrombopoietin: the primary regulator of megakaryocyte and platelet production
HK1060146A (en) Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
Jenkins et al. Activating point mutations in the common beta subunit of the human GM‐CSF, IL‐3 and IL‐5 receptors suggest the involvement of beta subunit dimerization and cell type‐specific molecules in signalling.
JP5012926B2 (ja) Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質
US7371569B2 (en) Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
AU2001282376A1 (en) Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
AU751498B2 (en) flt3 ligand chimeric proteins
US5686576A (en) Differentiated megakaryocyte line producing novel megakaryocyte differentiation factor
Baatout Thrombopoietin: a review
Lodish et al. The erythropoietin receptor: dimerization, activation, and tumorigenesis
AU749175B2 (en) Thrombopoietin
Kaushansky Physiology and preclinical studies of thrombopoietin
AU782245B2 (en) Thrombopoietin
JP4524816B2 (ja) Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質
JP3689111B2 (ja) インターロイキン１５
KR100607613B1 (ko) 트롬보포이에틴
Freeburn A study of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) in leukaemia
KR20040065249A (ko) 트롬보포이에틴
Buchli Biological and receptor binding properties of interleukin-2 analogs employing site-directed mutagenesis and filamentous phage display
CZ346799A3 (cs) Chimérické proteiny jako flt3 ligandy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030324

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20031127

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROBELLO PORTO, CARLOS, ALBERTO

Inventor name: PRITSCH ALBISU, OTTO, FRANZ

Inventor name: CAYOTA GUZIKOVSKY, ALFONSO

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60115063

Country of ref document: DE

Date of ref document: 20051222

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060216

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: FREI PATENTANWALTSBUERO

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2253411

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051116

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100824

Year of fee payment: 10

Ref country code: NL

Payment date: 20100824

Year of fee payment: 10

Ref country code: IE

Payment date: 20100823

Year of fee payment: 10

Ref country code: ES

Payment date: 20100827

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20100812

Year of fee payment: 10

Ref country code: SE

Payment date: 20100824

Year of fee payment: 10

Ref country code: IT

Payment date: 20100825

Year of fee payment: 10

Ref country code: FR

Payment date: 20100910

Year of fee payment: 10

Ref country code: DE

Payment date: 20100819

Year of fee payment: 10

Ref country code: AT

Payment date: 20100823

Year of fee payment: 10

Ref country code: FI

Payment date: 20100823

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100824

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20100820

Year of fee payment: 10

Ref country code: DK

Payment date: 20100824

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20100825

Year of fee payment: 10

BERE Be: lapsed

Owner name: *PRITSCH ALBISU OTTO FRANZ

Effective date: 20110831

Owner name: *BATTHYANY DIGHIERO CARLOS IGNACIO EDMUNDO

Effective date: 20110831

Owner name: *CAYOTA GUZIKOVSKY ALFONSO

Effective date: 20110831

Owner name: *ROBELLO PORTO CARLOS ALBERTO

Effective date: 20110831

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120223

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120223

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120301

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60115063

Country of ref document: DE

Effective date: 20120301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20121207

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 310081

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823